Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 313-320

  Gnant, Michael ^a   Mlineritsch, B ^b   Stoeger, H ^c   Luschin Ebengreuth, G ^c   Knauer, M ^d   Moik, M ^b   Jakesz, R ^a   Seifert, M ^a   Taucher, S ^e   Bjelic Radisic, V ^c   Balic, M ^c   Eidtmann, H ^f   Eiermann, W ^g   Steger, G ^a   Kwasny, W ^h   Dubsky, P ^a   Selim, U ⁱ   Fitzal, F ^a   Hochreiner, G ^j   Wette, V ^k   Sevelda, P ^l   Ploner, F ^c   Bartsch, R ^a   Fesl, C ^m   Greil, R ^b   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Hospital of the Sisters of Charity   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g Gynecology and Gynecological Oncology IOZ Mu nchen   (Germany)

^h Hospital Wiener Neustadt   (Austria)

ⁱ HANUSCH HOSPITAL   (Austria)

^j KEPLER UNIVERSITY HOSPITAL   (Austria)

^k Practice of DrWette ^*  (Austria)

^l Neurological Center Rosenhuegel   (Austria)

^m Austrian Breast and Colorectal Cancer Study Group   (Austria)

more..

Author keywords

Anastrozol; Bisphosphonates; Early breast cancer; LHRH agonists; Tamoxifen; Zoledronic acid

Indexed keywords

ANASTROZOLE; GOSERELIN; TAMOXIFEN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; AUSTRIAN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; OVARY FUNCTION; OVERALL SURVIVAL; OVULATION INHIBITION; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; BREAST NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; PREMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 84925337899     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu544     Document Type: Article

References (31)

1. Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel) 2013; 8: 102-109.
2. Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47: 683-689.
3. Nicks KM, Fowler TW, Akel NS et al. Bone turnover across the menopause transition: the role of gonadal inhibins. Ann N Y Acad Sci 2010; 1192: 153-160.
4. Fogelman I, Blake GM, Blamey R et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003; 14: 1001-1006.
5. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057.
6. Brufsky AM, Harker WG, Beck JT et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118: 1192-1201.
7. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9: 840-849.
8. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13.
9. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11: 421-428.
10. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34: 453-475.
11. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
12. Gnant M, Mlineritsch B, Stoeger H et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-641.
13. Eidtmann H, de Boer R, Bundred NJ et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010; 21: 2188-2194.
14. Coleman R, de Boer R, Eidtmann H et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405.
15. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
16. Chlebowski RT, Chen Z, Cauley JA et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010; 28: 3582-3590.
17. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010; 102: 799-802.
18. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010; 28: 3577-3581.
19. Rack B, Ju¨ckstock J, Genss EM et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010; 30: 1807-1813.
20. Brown JE, Ellis SP, Lester JE et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007; 13: 5406-5410.
21. Gnant M, Mlineritsch H, Stoeger H et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: long-term results from ABCSG-12. In Presented at the ASCO 47th Annual Meeting, Chicago, IL, 3-7 June 2011 (poster 520).
22. Gnant M, Clezardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev 2012; 38: 407-415.
23. Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-1326.
24. Coleman R, Gnant M, Morgan G et al. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012; 104: 1059-1067.
25. Paterson AH, Anderson SJ, Lembersky BC et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742.
26. Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. In Presented at the 36th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 10-14 December 2013 (abstr S4-07).
27. von Minckwitz G, Mobus V, Schneeweiss A et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3531-3539.
28. Kristensen B, Ejlertsen B, Mouridsen HT et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008; 47: 740-746.
29. Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AM. Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance. Curr Pharm Des 2014; 20: 6575-6583.
30. Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118.
31. Pfeiler G, Koenigsberg R, Fesl C et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29: 2653-2659.